January 24, 2022 -- TriSalus Life Sciences has entered a strategic research collaboration with the University of Colorado Anschutz Medical Campus (CU Anschutz). The collaboration will leverage TriSalus' immunotherapy platform, which integrates immunotherapeutics and drug delivery technology, to address the unique challenges of treating tumors in the liver and pancreas.
Over the next three years, TriSalus will collaborate with CU Anschutz on studies using TriSalus' proprietary pressure-enabled drug delivery (PEDD) method for the administration of an investigational toll-like receptor 9 agonist, SD-101. Preclinical and clinical studies involving this platform aim to build on scientific knowledge around treatments available for cancers of the liver and pancreas and enable more patients to benefit from immunotherapy.
In collaborating with TriSalus, CU Innovations will lead the establishment of the business relationship, while the CU Anschutz research team will focus on creating clinical research to advance TriSalus' approach.
TriSalus' platform consists of an investigational immunotherapy, SD-101, that aims to reactivate the immune system within the organs for targeted tumor killing, along with the PEDD method that modulates pressure and flow within blood vessels to improve therapy uptake and tumor response.
No financial details were disclosed.